Pharma slow to adopt SE incorporation
Interviewee/Contributor
William Ellington
Organisation
MedNous
Research Directory
How surrogate markers impact drug development
Interviewee/ContributorShiva MemariOrganisationVertical KnowingCurbing the use of unproven cellular therapies
Interviewee/ContributorMassimo DominiciOrganisationInternational Society Cell and Gene TherapyOwnership lessons for European biotechs
Interviewee/ContributorJohn RountreeOrganisationNovasectaSourcing antibiotics from the nematode worm
Interviewee/ContributorPhilippe Villain-GuillotOrganisationNosopharm SASInnovation spreads across the oncology sector
Interviewee/ContributorBruno PagliaraOrganisationOn-kòs Pharma ConsultingEuropean pharma plans new strategies for R&D
Interviewee/ContributorJean-Claude MullerOrganisationMedNousUsing nanotechnology to improve AIDS medication
Interviewee/ContributorPeter CharlishOrganisationMedNousPatch up the pain: A case study in transdermal drug delivery
Interviewee/ContributorVasiliki Nikolaou and David HaddletonOrganisationMedherant LtdNon-governmental drug assessments in the US
Interviewee/ContributorSteven PearsonOrganisationInstitute for Clinical and Economic Review